Gilead Sciences - Big Biotech's Stock Report

Company: Gilead Sciences
Starting stock price: $32.16
Ending stock price: $46.01
Percent Change: 43.06%

Scoop: Gilead's big achievement of '07 was the FDA approval of Letairis, a hypertension drug that marked the company's entry into the lucrative cardiovascular space. The company reported strong Phase III results for aztreonam lysine for cystic fibrosis, and Gilead's late-stage hepatitis B treatment Viread is closing in on FDA approval. Booming sales and an EU approval of HIV treatment Atripla rounded out a great year for Gilead.

Current stock price (3/25): $51.01

Gilead Sciences - Big Biotech's Stock Report

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.